Alan Brochstein wrote the BS article "Cannabics Pharmaceuticals Triggers Regulatory Scrutiny After Parabolic Spike" that caused CNBX to fall from $ 7+.
When I contacted the OTC board about his claims of "scrutiny" and provided them his article, they replied with the following denouncement that there had been no "scrutiny" of CNBX and stated that they believed Brochstein's article was a statement from CNBX, which it obviously was not.
Here is their reply regarding his article and their views of Brochstein speaking with any knowledge. Keep in mind the article title above regarding "Regulatory Scrutiny":
"Thank you for your email. Please note that OTC Markets has never announced a review of any nature regarding the company; and for further clarification, OTC Markets Group is not a regulatory agency. The links you included reference the company’s press release disseminated on February 23, 2017.
Please let us know if you have any additional questions.
Sincerely,
Gareth Colglazier OTC Markets Group 100 M Street SE, Suite 220 / Washington, DC 20003 Office: (212) 896-4458 Email: gareth@otcmarkets.com"
So Brochstein claimed "regulatory scrutiny" of CNBX where there was none, and when I included his article in my email to OTC, (full article linked below), they thought it was from CNBX. Anyone that read the article would know CNBX did not put this out.
In short, Brochstein has already proven in the last 90 days to be a person that likes to claim knowledge he does not have, claim "regulatory scrutiny" where there has been none, and when his articles are provided to the OTC Board, they denounce him as probably a nut working to stir up CNBX or MM news and nothing more.
He has cost us enough. Do not give someone that OTC has gone on record as not having the knowledge he claims to have any more credence than he has already falsely given himself.
News 
Market Data 
Discover 
AI
